Barclays analyst Matt Miksic raised the firm’s price target on Insulet (PODD) to $301 from $300 and keeps an Equal Weight rating on the shares. The firm updated the company’s estimates.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- PODD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Insulet’s New Study on Simplified Onboarding for Type 2 Diabetes Management: A Potential Game Changer
- Insulet’s Omnipod 5 Study: A Real-World Evaluation of Diabetes Management
- Insulet’s Omnipod 5 SA2.0 Study: A Leap in Diabetes Management
- Insulet Appoints Robbie Huffines as New Director